Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership
Advertisement
Tripos, Inc. announced that it has entered a strategic partnership with Sanofi-Synthelabo Recherche, an affiliate of Sanofi-Aventis.
Sanofi-Synthelabo Recherche has identified a number of proprietary chemistry motifs that exhibit therapeutic potential in a wide range of target areas. Tripos will employ its knowledge-driven chemistry approach to design and synthesize compounds that expand these areas. Tripos' high-throughput medicinal chemistry process will enable the rapid synthesis of those compounds to meet Sanofi-Synthelabo Recherche's project time frame requirements.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.